This medication is commonly used to help with the localized, supportive management of internal and external hemorrhoids, conditions that may be characterized by acute discomfort and localized vascular changes. The combination of a local anesthetic and a vasoprotective agent is a recognized pharmacological classification for this type of therapy.

Symptomatic Relief of Acute Discomfort

The product is generally used to help with symptoms related to physical discomfort, such as localized pain, throbbing, burning sensation, and persistent itching (pruritus). It is considered relevant for use across conditions involving inflammatory or irritative states where symptoms may intensify temporarily, and is applied in scenarios requiring supportive management of localized tissue swelling (edema) and capillary fragility. The combination therapy contributes to easing the overall symptom burden, which may assist with localized physical manifestations.

Management in Clinical Contexts

It is relevant when supportive symptom management is appropriate in conditions where symptoms may intensify temporarily, such as during the postpartum phase or in specific adult patient groups undergoing conservative therapy.

---

Quick Fact: Relief for Acute Sensory Symptoms The product may be applied when symptomatic relief is needed for pain, burning, and itching that interfere with daily functioning.

Regulatory References

1. National Cancer Institute (NCI) Drug Dictionary

Eligibility Map: Who can and cannot use Procto-Hemolan — Official Regulatory Information

---

The eligibility for Procto-Hemolan products is defined by official regulatory documentation, primarily establishing absolute exclusions based on known allergies and specific restrictions for vulnerable populations.

Contraindicated Populations

Use of any Procto-Hemolan product is contraindicated for any individual with a documented hypersensitivity (allergy) to the active substance(s) or any of the other ingredients (excipients) in that specific product form (e.g., tablet, cream, or suppository).

For products containing lidocaine (such as the cream and suppositories), a specific contraindication applies to those with known allergy to local amide anesthetics.

Restricted Populations

Population/Condition	Eligibility Status (Regulatory Basis)
Children	Not Recommended/Contraindicated. Should not be used due to a lack of safety data in this age group.
Pregnancy (First 3 Months)	Not Recommended/Should Not Be Used. For the rectal forms, use is generally advised against during the first trimester.
Pregnancy (After 3 Months)	Restricted. May be used from the 4th month onward, but only if necessary and in consultation with a doctor or pharmacist.
Breastfeeding/Lactation	Restricted. Use requires consultation with a doctor or pharmacist. For the tablet form (Procto-Hemolan Control), use is not recommended due to a lack of data on passage into breast milk.

All individuals must consult a healthcare professional if symptoms persist or worsen after short-term use, typically defined as seven days.

Interactions with other medicines and products

Official regulatory information for Procto-Hemolan (Lidocaine Hydrochloride and Tribenoside rectal cream) focuses primarily on documented pharmacodynamic interactions related to the active component, Lidocaine. This profile is constrained by the local route of administration and specific regulatory statements regarding formal interaction data.

The prescribing information notes a specific risk of additive toxic effects when the Lidocaine component is co-administered with certain classes of cardiac medicines. This is a pharmacodynamic interaction concern, involving potential effects such as myocardial depression.

Interaction Type	Interacting Medicinal Product Categories	Official Regulatory Concern
Pharmacodynamic Risk	Beta Blockers	Potential for additive toxic effects
Pharmacodynamic Risk	Other Antiarrhythmic Drugs	Potential for additive toxic effects

Crucially, regulatory documents state that no formal interaction studies have been performed for this combination product. As a result, specific pharmacokinetic interactions, such as those involving CYP enzymes that could alter the drug's exposure (AUC/Cmax) or clearance, are not formally documented in the label.

There are no medicinal product combinations formally classified as contraindicated due to an interaction risk. Furthermore, the official label does not document any mandatory timing requirements for dose separation, nor does it list specific interactions with food, alcohol, herbal products, or dietary supplements.

Action on Vascular Integrity and Capillary Permeability

Active components exert an effect on the vascular endothelium, acting to stabilize capillary structure and inhibit microvascular permeability. This action influences local tissue fluid dynamics by limiting the transcapillary movement of fluid and components into the interstitial space.

---

Targeted Blockade of Sensory Nerve Signals

Another component acts as a membrane stabilizer, targeting the voltage-gated sodium channels on sensory nerve endings. By binding to these channels, the drug blocks the rapid influx of sodium ions necessary for action potential generation. This process leads to the temporary interruption of sensory signal transmission, resulting in local desensitization of the application site.

---

Effect on Local Tissue Fluid Balance

This activity is a direct consequence of the drug's effect on microvascular integrity, specifically reducing the outward filtration of plasma fluid and proteins across vessel walls. By restricting transcapillary fluid movement, the mechanism reduces the passive accumulation of interstitial fluid and components.

How to Use Procto-Hemolan

This section outlines the administration guidelines for Procto-Hemolan (Tribenoside 50 mg/ g and Lidocaine Hydrochloride 20 mg/ g Rectal Cream).

---

Administration and Dosing Schedule

Usage Element	Standard Guideline
Route of Administration	Local rectal administration, suitable for both topical (perianal) and intrarectal (internal) use.
Standard Single Dose	A strip of cream approximately 1 cm in length is applied to the affected area.
Initial Frequency	Applied twice a day (morning and evening) during the acute phase.
Maintenance Frequency	Reduced to once a day after the acute symptoms have subsided.

---

Procedural and Population Constraints

The correct application of the cream necessitates specific preparatory steps and adherence to defined limits.

• Preparation: The application area must be thoroughly cleaned and dried before the cream is administered.
• Internal Method: Intrarectal administration must utilize the provided applicator, which requires cleaning after each use.
• Duration Constraint: Self-medication for the first episode of symptoms should not exceed 7 consecutive days.
• Age-Group Rule: Use of this preparation is restricted to adult patients; it is deemed not suitable for children.

These instructions define the standardized pattern of local use, governing the required frequency, dosage amount, application technique, and the time constraint for self-administration.

Research Evidence / Overview of Studies for Procto-Hemolan

Evidence Base for the Local Supportive Management of Hemorrhoids

Research available for the combination of Lidocaine Hydrochloride and Tribenoside has primarily involved short-term Randomized Controlled Trials (RCTs) and comparative studies. This research was evaluated in studies examining patient-reported experiences in Adults with low-grade hemorrhoidal conditions. Studies examined patient-reported outcomes for subjective discomfort, including the monitoring of pain, burning sensation, and persistent itching (pruritus).

Studies reported measurements detailing how symptoms evolved in the observed populations during the short treatment period. Research describes the changes measured during the study period, including those related to patient reports of pain and itching. Findings describe patterns observed in the studies related to subjective reports of discomfort and tracked objective outcomes such as localized swelling (edema). The evidence base includes multiple studies focused on these short-term, acute symptomatic endpoints.

Research on Acute Symptom Relief and Action Speed

The combination medicine was evaluated in studies exploring short-term symptom changes, focusing on conditions associated with acute or disruptive episodes. The studies primarily focused on how quickly the local anesthetic component begins to act and the total length of time a reduction in sensation was reported by patients. Data show patterns related to the monitored speed of onset for the localized anesthetic action, which was observed in some studies.

Evidence in Specific Patient Groups

Research has explored the use of the combination in postpartum women experiencing hemorrhoids related to pregnancy and delivery. Studies monitored outcomes related to physical discomfort in this specific population. Reported observations described the measured changes in edema and general tissue state in the observed postpartum groups. However, the total volume of evidence specific to this group is limited when compared to the research available for the general adult population.

Understanding the Research Landscape and Gaps

Long-term effects are not fully established. Follow-up durations were limited in the core efficacy studies, meaning there is limited information for long-term outcomes or data describing the persistence of observed changes after the treatment course concludes. Data show patterns related to low-grade hemorrhoidal conditions, and subgroup findings for higher severity levels remain uncertain. Research highlights what is known—and what is still uncertain—about this combination medicine.

Key Studies & References

1. Definition of lidocaine mixture with tribenoside (Authoritative Drug Definition and Components)

How to Store and Dispose of Procto-Hemolan?

The storage and disposal requirements for Procto-Hemolan rectal cream are strictly defined in the product's official regulatory labeling to ensure stability and safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at a temperature below 25°C or not above 30°C and do not freeze
Stability	Do not use after the expiry date; the shelf life for the unopened product is 5 years
Protection	Store in the original package and keep out of the sight and reach of children

Disposal Instructions

Official instructions prohibit discarding unused or expired Procto-Hemolan via wastewater or household waste. To ensure environmental protection, users are directed to ask a pharmacist how to dispose of the medicine that is no longer needed.